<DOC>
	<DOCNO>NCT01113801</DOCNO>
	<brief_summary>The purpose study determine LY2382770 safe effective protect kidney function participant kidney disease due diabetes .</brief_summary>
	<brief_title>A Study Participants With Diabetic Kidney Disease</brief_title>
	<detailed_description>The primary objective determine LY2382770 , administer monthly 1 year , effective placebo slow progression diabetic kidney disease participant treat angiotensin-converting enzyme inhibitor ( ACEi ) angiotensin II receptor blocker ( ARB ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Main Participants chronic kidney disease presume due diabetes Type 1 Type 2 Participants certain level kidney function serum creatinine ( SCr ) 1.3 3.3 mg/dl ( 115 291 micromol/L ) inclusive woman 1.5 3.5 mg/dl ( 132 309 micromol/L ) inclusive men , eGFR 20 60 mL/min/1.73 mÂ² Participants protein urine 24hour urine protein/creatinine ratio ( PCR ) great equal 800 mg/g ( great equal 91 mg/mmol ) . Participants must stable acceptable dose ACE ( angiotensinconverting enzyme ) inhibitor ARB ( angiotensin II receptor blocker ) , able tolerate medication . Main Female participants become pregnant , pregnant breastfeeding Participants follow medical condition ( site research staff discus criterion determine patient 's ability participate ) Chronic inflammatory autoimmune diseases Chronic Kidney Disease cause diabetes An organ transplant Too high blood pressure Viral Hepatitis B C liver infection , liver cirrhosis , significant liver disease Recent gastrointestinal bleeding Acute kidney injury within 3 month screen Major surgery within 3 month screen plan study period HIV infection virus cause AIDS Heart disease consider stable Cancer recent condition pose high risk develop cancer Required take drug change immune system</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Diabetic Kidney Disease</keyword>
	<keyword>End-Stage Renal Disease</keyword>
	<keyword>Transforming Growth Factor beta 1 Monoclonal Antibody</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Type 2 Diabetes</keyword>
</DOC>